Marilena Vrana on IPAW 2025: Celebrating Plasma Donors and Saving Lives
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, shared a post on LinkedIn:
“During International Plasma Awareness week (6-10 October), I invite you to celebrate donors, raise awareness, and highlight how Plasma Powers Possibility.
Plasma is one of medicine’s most vital yet often overlooked resources. It cannot be manufactured in a lab, making healthy and reliable donors critical to patient well being.
Every donation is a lifeline that powers treatments for immune deficiencies, bleeding disorders, neurological conditions, severe burns, organ transplants, and more.
Did you know?
- 130 donations are needed to treat just one person with primary immunodeficiency for a year
- 900 for alpha-1 antitrypsin deficiency.
- 1200 for haemophilia
Each act of generosity sustains lives today and builds hope for tomorrow. As patient Dave, living with CIDP, shared: ՛Intravenous Immunoglobulin (IVIG) saved my quality of life; it has given me a reason to keep trying.՛
How can you take part in this IPAW2025:
- Share patient and donor stories
- Use PlasmaPowersPossibility on social media
- Join local events to spread the word
Together, during IPAW2025 and beyond, we can ensure plasma-derived medicines remain available for the patients who depend on them.”
For more information check here.
Stay updated with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals